aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model.
Chong H KimSierra C SimmonsChau M BuiNing JiangHuy P PhamPublished in: Vox sanguinis (2018)
In high-titered AHA patients with bleeding, aPCC is a cost-effective treatment option when compared to rFVIIa. Thus, aPCC may be considered in these patients, if available, and provided there is no clinical contraindication.